Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30772963 | 1.00 | DYRK1A (0.60) | DYRK1AKDM4EPLA2G2ACNR1CNR2 | |
| SCHEMBL8866752 | 0.83 | DYRK1A (0.71) | DYRK1APLA2G2ACNR1CNR2HASPIN | |
| SCHEMBL25492005 | 0.80 | KDM4E (0.49) | DYRK1AKDM4E | |
| SCHEMBL600075 | 0.77 | CNR2 (0.72) | KDM4EPLA2G2ACNR1CNR2 | |
| SCHEMBL23148486 | 0.77 | KDM4E (0.57) | DYRK1AKDM4ECNR1CNR2 | |
| SCHEMBL30772939 | 0.76 | PARP10 (0.50) | KDM4E | |
| SCHEMBL20536372 | 0.76 | PARP10 (0.50) | KDM4E | |
| SCHEMBL23150407 | 0.75 | DYRK1A (1.00) | DYRK1AHASPIN | |
| SCHEMBL8867509 | 0.74 | MTNR1A (0.51) | DYRK1APLA2G2A | |
| P-Anisic Acid SCHEMBL30811191 | 0.73 | CA1 (0.74) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609867-B1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS INC (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-110753683-B | Carbazole compounds and methods of use thereof | 吉斯诺治疗公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| EP-3609867-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Saje Pharma, LLC (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110753683-A | Carbazole compounds and methods of use thereof | 赛吉制药有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2018191418-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | SAJE PHARMA, LLC (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSR, CBR3, CBR1 | DYRK1A 3058/4885KDM4E 3228/4885PLA2G2A 3349/4885 |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSR, CBR3, CBR1 | DYRK1A 3058/4885KDM4E 3228/4885PLA2G2A 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.